ArticlemBio2019
A Single Salt Bridge in VIM-20 Increases Protein Stability and Antibiotic Resistance under Low-Zinc Conditions.
Open access · goldAbstract read
In one paragraph
Article in mBio, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 25 citations in OpenAlex.
- The immune-microbe-metal triad: a vicious cycle driving biomaterial corrosion in the oral inflammatory microenvironment.Bioactive materials · 2027Review
- Immune surveillance interrupted: how cancer exploits trogocytosis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Zinc starvation uncovers bacterial host-specific proteases that shape NDM adaptability inmBio · 2026Article
- Mutation of an active site-adjacent residue in VIM indirectly dictates interactions with and blunts inhibition by D-captopril.Journal of inorganic biochemistry · 2025Article
- Genetic diversity, biochemical properties, epidemiology, and detection methods of IMP- and VIM-type carbapenemases.Clinical microbiology reviews · 2025Review
- Inhibitor Affinity Differs among Clinical Variants of IMP Metallo-ACS infectious diseases · 2025Article
- Exploiting the fitness cost of metallo-β-lactamase expression can overcome antibiotic resistance in bacterial pathogens.Nature microbiology · 2025Article
- Zinc-dependent β-lactam resistance at a cost.Nature microbiology · 2025Article
- Machine Learning Models Identify Inhibitors of New Delhi Metallo-β-lactamase.Journal of chemical information and modeling · 2024Article
- Structural insights into the design of reversible fluorescent probes for metallo-β-lactamases NDM-1, VIM-2, and IMP-1.Journal of inorganic biochemistry · 2022Article
- Metallo-β-lactamases and a tug-of-war for the available zinc at the host-pathogen interface.Current opinion in chemical biology · 2022Review
- Detection and Characterization of VIM-52, a New Variant of VIM-1 from a Klebsiella pneumoniae Clinical Isolate.Antimicrobial agents and chemotherapy · 2021Article
- Metallo-β-lactamases in the Age of Multidrug Resistance: From Structure and Mechanism to Evolution, Dissemination, and Inhibitor Design.Chemical reviews · 2021Review
- Spectroscopic and biochemical characterization of metallo-β-lactamase IMP-1 with dicarboxylic, sulfonyl, and thiol inhibitors.Bioorganic & medicinal chemistry · 2021Article
- Visualizing the Dynamic Metalation State of New Delhi Metallo-β-lactamase-1 in Bacteria Using a Reversible Fluorescent Probe.Journal of the American Chemical Society · 2021Article
- Carbapenem Use Is Driving the Evolution of Imipenemase 1 Variants.Antimicrobial agents and chemotherapy · 2021Article
- Structural Comparisons of Cefotaximase (CTX-M-ase) Sub Family 1.Frontiers in microbiology · 2021Review
- Therapeutic Options for Metallo-β-Lactamase-Producing Enterobacterales.Infection and drug resistance · 2021Review
- Iminodiacetic Acid as a Novel Metal-Binding Pharmacophore for New Delhi Metallo-β-lactamase Inhibitor Development.ChemMedChem · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 1 country.
Zishuo Cheng *Department of Chemistry and Biochemistry, Miami University, Oxford, Ohio, USA.
Ben A Shurina *Department of Chemistry and Biochemistry, Miami University, Oxford, Ohio, USA.
Christopher R Bethel *Research Services, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Pei W ThomasDivision of Chemical Biology and Medicinal Chemistry, College of Pharmacy, and the LaMontagne Center for Infectious Disease, University of Texas, Austin, Texas, USA.
Steven H MarshallResearch Services, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Caitlyn A ThomasDepartment of Chemistry and Biochemistry, Miami University, Oxford, Ohio, USA.
Kundi YangDepartment of Chemistry and Biochemistry, Miami University, Oxford, Ohio, USA.
Robert L KimbleDepartment of Chemistry and Biochemistry, Miami University, Oxford, Ohio, USA.
Jonathan S MontgomeryDepartment of Chemistry and Biochemistry, Miami University, Oxford, Ohio, USA.
Matthew G OrischakDepartment of Chemistry and Biochemistry, Miami University, Oxford, Ohio, USA.
Callie M MillerDepartment of Chemistry and Biochemistry, Miami University, Oxford, Ohio, USA.
Jordan L TennenbaumDepartment of Chemistry and Biochemistry, Miami University, Oxford, Ohio, USA.
Jay C NixMolecular Biology Consortium, Beamline 4.2.2, Advanced Light Source, Lawrence Berkeley National Laboratory, Berkeley, California, USA.
David L TierneyDepartment of Chemistry and Biochemistry, Miami University, Oxford, Ohio, USA.
Walter FastDivision of Chemical Biology and Medicinal Chemistry, College of Pharmacy, and the LaMontagne Center for Infectious Disease, University of Texas, Austin, Texas, USA walt.fast@austin.utexas.edu robert.bonomo@va.gov pagerc@miamioh.ed crowdemw@miamioh.edu.ORCID 0000-0001-7567-2213
Robert A BonomoResearch Services, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA walt.fast@austin.utexas.edu robert.bonomo@va.gov pagerc@miamioh.ed crowdemw@miamioh.edu.
Richard C PageDepartment of Chemistry and Biochemistry, Miami University, Oxford, Ohio, USA walt.fast@austin.utexas.edu robert.bonomo@va.gov pagerc@miamioh.ed crowdemw@miamioh.edu.ORCID 0000-0002-3006-3171
Michael W CrowderDepartment of Chemistry and Biochemistry, Miami University, Oxford, Ohio, USA walt.fast@austin.utexas.edu robert.bonomo@va.gov pagerc@miamioh.ed crowdemw@miamioh.edu.
Miami University · USLouis Stokes Cleveland VA Medical Center · USLawrence Berkeley National Laboratory · US
Funding
Understanding B-Lactam Resistance in Acinetobacter baumanniiR01AI072219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROBERT A. BONOMO, Philip N. Rather · 2007 to 2026
$6.6MUnderstanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9MA Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4MTriage mechanisms for directing protein refolding and degradationR35GM128595 · NIGMS · MIAMI UNIVERSITY OXFORD · PI Richard C Page · 2018 to 2026
$2.8MDeveloping Metallo-Beta-Lactamase InhibitorsR01GM111926 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI BONOMO, ROBERT A., COHEN, SETH M · 2015 to 2019
$2.3MMachine Learning Approach for finding novel metallo-b-lactamase inhibitorsR15GM134454 · NIGMS · MIAMI UNIVERSITY OXFORD · PI CROWDER, MICHAEL W · 2019 to 2022
$867kMolecular Epidemiology of Carbapenem-Resistant Klebsiella pneumoniaeR21AI114508 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., VAN DUIN, DAVID · 2015 to 2016
$445kThe Continuing Challenge of Carbapenemases in K. pneumoniae: KPC-2 & NDM-1I01BX001974 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI BONOMO, ROBERT A. · 2013 to 2024
–BLRD VA I01 BX001974NIAID NIH HHS R01 AI063517NIAID NIH HHS R01 AI072219NIAID NIH HHS R01 AI100560NIAID NIH HHS R21 AI114508NIGMS NIH HHS R01 GM111926NIGMS NIH HHS R15 GM134454NIGMS NIH HHS R35 GM128595
Abstract
To understand the evolution of Verona integron-encoded metallo-β-lactamase (VIM) genes (
Indexed as
Drug Resistance, Bacterialbeta-LactamasesCarbapenemsEscherichia coliHumansMicrobial Sensitivity TestsModels, MolecularMutationProtein ConformationProtein StabilityZincbeta-LactamasesCarbapenemsZinccarbapenem resistancemetallo-β-lactamaseprotein stabilitysalt bridgeVIMVIM-20zinc
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.